29 Sept 2022
Normally used to treat cardiovascular disease, the mineralocorticoid antagonist spironolactone has now shown efficacy in decreasing alcohol intake. The study investigated the effects on alcohol consumption in mice, rats and people and is published in Molecular Psychiatry.
Study links premature ovarian insufficiency (POI) to risk of mortality
17 May 2024
Cardiovascular disease mortality associated with low testosterone in men
17 May 2024
People with obesity using semaglutide see cardiovascular improvements
17 May 2024
Men with obesity lose more weight with cash incentives, research says
17 May 2024
Research Assistant in Endocrinology (University of Sheffield)
14 May 2024